Jan 8 (Reuters) - Matinas Biopharma Holdings Inc:
* MATINAS BIOPHARMA ACHIEVES STATISTICAL ENDPOINT FOR SUCCESS IN PHASE 2A CLINICAL STUDY OF ORALLY-ADMINISTERED MAT2203 FOR THE TREATMENT OF CHRONIC REFRACTORY MUCOCUTANEOUS CANDIDIASIS
* MATINAS BIOPHARMA - ‍INVESTIGATORS FROM NATIONAL INSTITUTES OF HEALTH RELAYED POSITIVE DATA FROM THIRD PATIENT ENROLLED IN PHASE 2A STUDY OF MAT2203​
* MATINAS BIOPHARMA HOLDINGS INC - THE THIRD PATIENT MET PRIMARY ENDPOINT OF PHASE 2A STUDY WITH TREATMENT OF MAT2203​ Source text for Eikon: Further company coverage:
 